|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.680 USD | -0.30% |
|
+10.78% | -18.34% |
| Jun. 29 | Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2026 | CI |
| Jun. 25 | Helus Pharma Closes $50 Million Underwritten Offering | MT |
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (USD) |
|---|---|---|---|---|---|---|---|
Profitability | |||||||
Return on Assets | -45.29 | -46.68 | -27.69 | -31.92 | -41.35 | ||
Return on Total Capital | -49.17 | -51.77 | -28.95 | -33.8 | -44.92 | ||
Return On Equity % | -83.35 | -76.36 | -45.91 | -42.76 | -74.6 | ||
Return on Common Equity | -83.35 | -76.36 | -45.91 | -42.76 | -74.6 | ||
Margin Analysis | |||||||
Gross Profit Margin % | - | - | - | - | - | ||
SG&A Margin | - | - | - | - | - | ||
EBITDA Margin % | - | - | - | - | - | ||
EBITA Margin % | - | - | - | - | - | ||
EBIT Margin % | - | - | - | - | - | ||
Income From Continuing Operations Margin % | - | - | - | - | - | ||
Net Income Margin % | - | - | - | - | - | ||
Net Avail. For Common Margin % | - | - | - | - | - | ||
Normalized Net Income Margin | - | - | - | - | - | ||
Levered Free Cash Flow Margin | - | - | - | - | - | ||
Unlevered Free Cash Flow Margin | - | - | - | - | - | ||
Asset Turnover | |||||||
Asset Turnover | - | - | - | - | - | ||
Receivables Turnover (Average Receivables) | - | - | - | - | - | ||
Short Term Liquidity | |||||||
Current Ratio | 7.38 | 4.09 | 21.65 | 7.75 | 9.52 | ||
Quick Ratio | 7.05 | 3.48 | 21.14 | 6.58 | 8.38 | ||
Operating Cash Flow to Current Liabilities | -5.72 | -8.38 | -6.83 | -4.73 | -6.88 | ||
Days Sales Outstanding (Average Receivables) | - | - | - | - | - | ||
Average Days Payable Outstanding | - | - | - | - | - | ||
Long Term Solvency | |||||||
Total Debt/Equity | - | - | 0.1 | - | - | ||
Total Debt / Total Capital | - | - | 0.1 | - | - | ||
Total Liabilities / Total Assets | 9.41 | 10.51 | 3.34 | 8.28 | 7.71 | ||
EBIT / Interest Expense | - | - | - | - | -48.88 | ||
EBITDA / Interest Expense | - | - | - | - | -48.84 | ||
(EBITDA - Capex) / Interest Expense | - | - | - | - | -48.91 | ||
Total Debt / EBITDA | - | - | -0 | - | - | ||
Net Debt / EBITDA | 0.84 | 0.32 | 2.66 | 0.95 | 1.1 | ||
Total Debt / (EBITDA - Capex) | - | - | -0 | - | - | ||
Net Debt / (EBITDA - Capex) | 0.84 | 0.32 | 2.66 | 0.95 | 1.1 | ||
Growth Over Prior Year | |||||||
EBITDA, 1 Yr. Growth % | 105.48 | -19.45 | 53.21 | 81.91 | 38.6 | ||
EBITA, 1 Yr. Growth % | 105.7 | -19.33 | 53.01 | 81.61 | 38.28 | ||
EBIT, 1 Yr. Growth % | 105.7 | -19.3 | 53.03 | 81.58 | 38.27 | ||
Earnings From Cont. Operations, 1 Yr. Growth % | 109.9 | -29.78 | 64.41 | 44.9 | 81.35 | ||
Net Income, 1 Yr. Growth % | 109.9 | -29.78 | 64.41 | 44.9 | 81.35 | ||
Normalized Net Income, 1 Yr. Growth % | 103.23 | -26.63 | 66.52 | 44.9 | 71.42 | ||
Diluted EPS Before Extra, 1 Yr. Growth % | 25.49 | -35.69 | -3.85 | -40.55 | 5.26 | ||
Accounts Receivable, 1 Yr. Growth % | - | - | - | - | - | ||
Net Property, Plant and Equip., 1 Yr. Growth % | -11.85 | -8.35 | 21.56 | -74.22 | 98.98 | ||
Total Assets, 1 Yr. Growth % | -8.74 | -35.88 | 460.37 | -14.37 | 39.62 | ||
Tangible Book Value, 1 Yr. Growth % | -16.16 | -64.88 | 1.06K | -30.76 | 64.27 | ||
Common Equity, 1 Yr. Growth % | -11.57 | -36.66 | 505.23 | -18.75 | 40.48 | ||
Cash From Operations, 1 Yr. Growth % | 137.59 | 4.92 | 45.28 | 47.01 | 84.26 | ||
Capital Expenditures, 1 Yr. Growth % | -22.22 | 35.24 | -85.21 | 66.67 | 623.08 | ||
Levered Free Cash Flow, 1 Yr. Growth % | 274.4 | 61.41 | -0.38 | 67.66 | 101.28 | ||
Unlevered Free Cash Flow, 1 Yr. Growth % | 274.81 | 61.41 | -0.38 | 67.66 | 96.84 | ||
Compound Annual Growth Rate Over Two Years | |||||||
EBITDA, 2 Yr. CAGR % | - | 28.65 | 11.09 | 66.95 | 59.09 | ||
EBITA, 2 Yr. CAGR % | 471.64 | 28.82 | 11.1 | 66.7 | 58.91 | ||
EBIT, 2 Yr. CAGR % | 471.64 | 28.84 | 11.13 | 66.69 | 58.89 | ||
Earnings From Cont. Operations, 2 Yr. CAGR % | 489.83 | 21.41 | 7.45 | 54.35 | 62.66 | ||
Net Income, 2 Yr. CAGR % | 489.83 | 21.41 | 7.45 | 54.35 | 62.66 | ||
Normalized Net Income, 2 Yr. CAGR % | 473.35 | 22.11 | 10.53 | 55.34 | 58.14 | ||
Diluted EPS Before Extra, 2 Yr. CAGR % | 190.21 | -10.16 | -21.36 | -24.74 | -20.58 | ||
Net Property, Plant and Equip., 2 Yr. CAGR % | - | -10.12 | 5.55 | -44.02 | -29.46 | ||
Total Assets, 2 Yr. CAGR % | 600.93 | -23.51 | 89.55 | 119.05 | 7.74 | ||
Tangible Book Value, 2 Yr. CAGR % | 494.52 | -45.74 | 102.07 | 183.75 | 5.09 | ||
Common Equity, 2 Yr. CAGR % | 625.21 | -25.16 | 95.79 | 121.76 | 5.28 | ||
Cash From Operations, 2 Yr. CAGR % | 471.36 | 57.89 | 23.46 | 46.14 | 64.31 | ||
Capital Expenditures, 2 Yr. CAGR % | - | 2.56 | -55.28 | -50.35 | 253.51 | ||
Levered Free Cash Flow, 2 Yr. CAGR % | - | 145.83 | 26.81 | 29.24 | 82.74 | ||
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | 145.97 | 26.81 | 29.24 | 80.71 | ||
Compound Annual Growth Rate Over Three Years | |||||||
EBITDA, 3 Yr. CAGR % | - | - | 36.37 | 30.94 | 57.11 | ||
EBITA, 3 Yr. CAGR % | - | 197.61 | 36.42 | 30.88 | 56.92 | ||
EBIT, 3 Yr. CAGR % | - | 197.65 | 36.44 | 30.89 | 56.91 | ||
Earnings From Cont. Operations, 3 Yr. CAGR % | - | 190.16 | 34.32 | 18.71 | 63.24 | ||
Net Income, 3 Yr. CAGR % | - | 190.16 | 34.32 | 18.71 | 63.24 | ||
Normalized Net Income, 3 Yr. CAGR % | - | 188.93 | 35.41 | 20.97 | 60.89 | ||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | 75.62 | -8.11 | -28.58 | -15.62 | ||
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | -0.6 | -34.02 | -15.43 | ||
Total Assets, 3 Yr. CAGR % | - | 215.82 | 48.56 | 45.44 | 86.67 | ||
Tangible Book Value, 3 Yr. CAGR % | - | 131.53 | 50.71 | 41.4 | 134.18 | ||
Common Equity, 3 Yr. CAGR % | - | 221.76 | 50.22 | 46.04 | 88.59 | ||
Cash From Operations, 3 Yr. CAGR % | - | 224.76 | 53.57 | 30.86 | 57.7 | ||
Capital Expenditures, 3 Yr. CAGR % | - | - | -46.22 | -30.66 | 22.72 | ||
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | 81.92 | 39.18 | 49.28 | ||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | 81.99 | 39.18 | 48.17 | ||
Compound Annual Growth Rate Over Five Years | |||||||
EBITDA, 5 Yr. CAGR % | - | - | - | - | 45.04 | ||
EBITA, 5 Yr. CAGR % | - | - | - | 136.03 | 45.01 | ||
EBIT, 5 Yr. CAGR % | - | - | - | 136.04 | 45.02 | ||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | 125.41 | 45.01 | ||
Net Income, 5 Yr. CAGR % | - | - | - | 125.41 | 45.01 | ||
Normalized Net Income, 5 Yr. CAGR % | - | - | - | 125.41 | 44.08 | ||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | 25.13 | -13.48 | ||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | - | -13.34 | ||
Total Assets, 5 Yr. CAGR % | - | - | - | 172.82 | 30.65 | ||
Tangible Book Value, 5 Yr. CAGR % | - | - | - | 151.15 | 30.47 | ||
Common Equity, 5 Yr. CAGR % | - | - | - | 177.25 | 30.31 | ||
Cash From Operations, 5 Yr. CAGR % | - | - | - | 135.96 | 57.78 | ||
Capital Expenditures, 5 Yr. CAGR % | - | - | - | - | 14.22 | ||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 82.25 | ||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 81.47 |
- Stock Market
- Stocks
- HELP Stock
- Financials Cybin Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















